**Moderna Shares Surge Following Trial Results**
On Wednesday, August 30, 2023, Moderna, Inc. (MRNA) experienced a significant stock surge of 177% after announcing positive Phase 3 trial results for its personalized mRNA cancer vaccine, developed in partnership with Merck & Company, Inc. (MRK) for melanoma patients. This sharp rally was bolstered by heavy short covering amid a seasonal dip in trading volume, drawing investor attention away from AI stocks without any substantial changes in those companies.
Investors looking to capitalize on market shifts might consider where to invest a hypothetical $10,000 today, as discussed in recent commentary from market analyst Louis Navellier.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
